4//SEC Filing
Palmer Pamela P 4
Accession 0001209191-21-018155
CIK 0001427925other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 3:34 PM ET
Size
11.2 KB
Accession
0001209191-21-018155
Insider Transaction Report
Form 4
Palmer Pamela P
DirectorChief Medical Officer
Transactions
- Award
Common Stock
2021-03-03+68,750→ 666,621 total - Award
Stock Option (Right to Buy)
2021-03-03+137,500→ 137,500 totalExercise: $1.88Exp: 2031-03-03→ Common Stock (137,500 underlying) - Award
Stock Option (Right to Buy)
2021-03-03+68,750→ 68,750 totalExercise: $1.88Exp: 2031-03-03→ Common Stock (68,750 underlying)
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The restricted stock units shall vest in three equal consecutive annual installments on March 3, 2022, March 3, 2023 and March 3, 2024.
- [F3]Balance includes acquisition of 4,773 shares of Common Stock through the Company's Employee Stock Purchase Plan.
- [F4]The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the date of grant and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months.
- [F5]On March 3, 2021, the Reporting Person was granted performance options subject to the satisfaction of share price targets over a performance period from March 3, 2021 to December 31, 2024 (the "Performance Period"), as determined by the Compensation Committee (the "Committee") of the Company's Board of Directors.
- [F6]The performance options shall be earned as follows: (i) 33% of the performance options if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals or exceeds $4.00, (ii) an additional 33% of the performance option if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals or exceeds $5.00, and (iii) 34% of the performance options if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals or exceeds $6.00. Once earned, the performance options will vest on the one-year anniversary of the date on which the Committee certified achievement of an applicable price target, so long as the reporting person remains in continuous service through such applicable vesting date.
Documents
Issuer
ACELRX PHARMACEUTICALS INC
CIK 0001427925
Entity typeother
Related Parties
1- filerCIK 0001511365
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 3:34 PM ET
- Size
- 11.2 KB